Idexx Laboratories (IDXX) Common Equity (2009 - 2026)

Idexx Laboratories' Common Equity history runs 18 years deep, the most recent figure standing at $1.6 billion for Q1 2026.

• In Q1 2026, Common Equity rose 7.46% year-over-year to $1.6 billion; the TTM figure through Mar 2026 stood at $1.6 billion (up 7.46% YoY), while the FY2025 annual figure was $1.6 billion, up 0.63% from the prior year.
• Common Equity for Q1 2026 stood at $1.6 billion, down from $1.6 billion in the prior quarter.
• The five-year high for Common Equity was $1.6 billion in Q3 2024, with the low at $457.0 million in Q2 2022.
• The 5-year median for Common Equity is $1.5 billion (2025), against an average of $1.2 billion.
• The sharpest annual moves came in 2022 and 2023: Common Equity tumbled 38.92% in 2022, then soared 172.57% in 2023.
• Idexx Laboratories' Common Equity stood at $608.7 million in 2022, then jumped by 143.87% to $1.5 billion in 2023, then advanced by 7.46% to $1.6 billion in 2024, then increased by 0.63% to $1.6 billion in 2025, then dropped by 3.07% to $1.6 billion in 2026.
• Business Quant data shows IDXX's Common Equity at $1.6 billion in Q1 2026, $1.6 billion in Q4 2025, and $1.6 billion in Q3 2025.